Bioindustry Regulations and Standards
What this domain tests
Bioindustry Regulations and Standards tests your command of the legal and standards framework around biotechnology in Japan and internationally. Questions may ask which law applies, which approval is required, or which standard governs a quality system.
Core rules
- In Japan, contained use and environmental release of genetically modified organisms are regulated under the Cartagena Act (「遺伝子組換え生物等の使用等の規制による生物の多様性の確保に関する法律」). Type 1 use is environmental release; Type 2 use is contained use. Approval and facility inspection requirements differ.
- The Infectious Disease Control Act (感染症法) controls handling of specified pathogens; the Industrial Safety and Health Act (労働安全衛生法) covers worker protection; the Poisonous and Deleterious Substances Control Act covers certain chemicals.
- Pharmaceutical manufacture falls under the Pharmaceuticals and Medical Devices Act (薬機法) and GMP; food under the Food Sanitation Act; animal and plant pathogens under the Livestock Infectious Disease Prevention Act and Plant Protection Act.
- International instruments include the Cartagena Protocol on Biosafety, the Nagoya Protocol on access and benefit-sharing, WHO Laboratory Biosafety Manual, and OECD best practice for biological resource centres.
- Standards are not interchangeable: ISO 9001 is quality management, ISO 20387 is biobanking, ISO 17025 is testing and calibration competence, ISO 13485 is medical devices, and GMP is product-specific.
Worked example
A company wants a field trial of a GM rice line in Japan. This is Type 1 use under the Cartagena Act because the organism will be released into the environment. The company must submit the required application, provide a biodiversity risk assessment, and await approval before planting. A contained greenhouse experiment would fall under Type 2 use with different containment and confirmation requirements. The reasoning is that the legal category follows the use, not the organism alone.
Traps that cost marks
- Assuming contained research is exempt from the Cartagena Act.
- Confusing Type 1 and Type 2 use.
- Treating ISO 9001 as a biosafety standard.
- Forgetting import/export and transport requirements.
- Missing record-retention or notification duties.